Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.58 |
| ▸ | BLM | P54132 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17241737 | 0.89 | MAPT (0.63) | P2RX4ALDH1A1HDAC1HDAC11HDAC8 | |
| SCHEMBL6266030 | 0.89 | P2RX4 (0.72) | P2RX4HDAC1SMN1; SMN2HDAC11HDAC8 | |
| SCHEMBL19555085 | 0.86 | MAPK8 (0.66) | P2RX4HDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL17241596 | 0.85 | TSHR (0.62) | P2RX4ALDH1A1HDAC1SMN1; SMN2TDP1 | |
| SCHEMBL6509732 | 0.85 | MEN1 (0.60) | HDAC1MEN1KMT2AMAPT | |
| SCHEMBL7652274 | 0.84 | P2RX4 (0.61) | P2RX4ALDH1A1HDAC1BLMSMN1; SMN2 | |
| SCHEMBL12963694 | 0.83 | HDAC1 (0.67) | P2RX4ALDH1A1HDAC1HDAC11HDAC8 | |
| SCHEMBL10085642 | 0.83 | TP53 (0.51) | ALDH1A1TDP1POLBLMNAKDM4E | |
| SCHEMBL17241700 | 0.83 | HDAC1 (0.60) | P2RX4ALDH1A1HDAC1HDAC11HDAC8 | |
| SCHEMBL7653389 | 0.83 | P2RX4 (0.60) | P2RX4ALDH1A1HDAC1BLMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137387-A1 | PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES | ORION CORPORATION (FI) | 2017-05-18 | — | — | US | claimed |
| US-20170137387-A1 | PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES | ORION CORPORATION (FI) | 2017-05-18 | — | — | US | disclosed |
| EP-3140301-A1 | PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES | Orion Corporation (FI) | 2017-03-15 | — | — | EP | disclosed |
| WO-2015169999-A1 | PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES | ORION CORPORATION (FI) | 2015-11-12 | — | — | WO | disclosed |
| EP-1530475-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 AND A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | Warner-Lambert Company LLC (US) | 2005-05-18 | — | — | EP | disclosed |
| US-20050004126-A1 | Method of determining potential allosterically-binding matrix metalloproteinase inhibitors | ANDRIANJARA CHARLES (FR) | 2005-01-06 | — | — | US | disclosed |
| WO-2004006931-A2 | PHARMACEUTICAL COMPOSTIONS COMPRISING AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 AND A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004126-A1 | Method of determining potential allosterically-binding matrix metalloproteinase inhibitors | MMP13, MMP12, MMP25 | P2RX4 4552/4885ALDH1A1 4241/4885HDAC1 370/4885 |
| US-20170137387-A1 | PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES | GABRB1, GABRB3, GABRB2 | P2RX4 158/4885ALDH1A1 819/4885HDAC1 1565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.